Previous Close | 0.0500 |
Open | 0.0500 |
Bid | 0.0500 x N/A |
Ask | 0.0550 x N/A |
Day's Range | 0.0500 - 0.0500 |
52 Week Range | 0.0350 - 0.1700 |
Volume | |
Avg. Volume | 251,405 |
Market Cap | 6.063M |
Beta (5Y Monthly) | 0.97 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.4140 |
Earnings Date | Feb 13, 2023 - Feb 17, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 0.30 |
HALIFAX, Nova Scotia, January 17, 2023--Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, has named Carl Gelhaus, Ph.D., as Director of Non-Clinical Research, and Arthur Baran, B.Sc., MBA, PMP, as Director of New Product Development including ATI-1701, a potential first-in-class vaccine candidate for the prevention of infection with aerosolized Francisella tularensis, whi
Announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance ...
HALIFAX, Nova Scotia, January 13, 2023--Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced that the United States Patent and Trademark Office ("USPTO") has issued a Notice of Allowance of new patent claims for ATI-1501, Appili’s liquid oral reformulation of the antibiotic metronidazole. A notice of allowance is issued by the USPTO to indicate that t